Clinical Research Directory

Inclusion Criteria: 1. Female breast cancer survivors aged 18-65 years. 2. Initially diagnosed with stage I-III non-metastatic breast cancer. 3. Between 6 months and 5 years after completion of initial curative surgery +/- radiation/chemotherapy. 4. allowed to be on endocrine therapy and/or anti-HER2 targeted therapy. 5. Self-reported cognitive complaints following cancer treatment. 6. Right-handedness (for standardized tDCS targeting) 7. Education level ≥ 6 years 8. Able and willing to undergo all study procedures (neuropsychological testing, MRI, EEG, etc.) and to provide written informed consent Exclusion Criteria: 1. Contraindications to MRI or EEG (e.g., pacemaker, metallic implants, claustrophobia). 2. Active neurological/psychiatric disorders (e.g., major depressive disorder, bipolar disorder, schizophrenia, Parkinson's disease, post-stroke sequelae) 3. Concurrent use of cognition-enhancing medications (e.g., donepezil, memantine) 4. Severe somatic diseases (cardiac/hepatic/renal insufficiency) 5. Pregnant or breastfeeding 6. Concurrent participation in another interventional clinical trial